ARCHIVES

An “insurgency” targets randomized trials, demands access to investigational drugs.

This article is from The Cancer Letter archive.

Vol. 31 No. 31 | August 5, 2005

Download PDF Visit The Full Archive

Related Articles

An Unusual Week Of Deals In Oncology: Alliances, Sales, and Dramatic Moves

November 13, 1998

Chabner Criticizes FDA Crackdown On Off-Label Info

June 28, 1991

Women Radiated For Wilms’ At Risk For Complications In Pregnancy, Study Finds

May 31, 2002

In Brief: Senate Committee Confirms Varmus; Albertini Directs Vermont Cancer Center

November 19, 1993

NCAB Subcommittee Oks Concept Of Five Recompetitions

October 23, 1981

FDA developing guidelines for oncology endpoints.

May 7, 2004